Board of Directors

James N. Cooper, M.D. – Chairman of the Board

Dr. Cooper is currently Director of Medical Research Development and Professor of Life Sciences at George Mason University. Previously, he was Assistant Dean and Professor of Medicine at the Georgetown University School of Medicine, as well as Professor of Medicine at the Virginia Commonwealth University. He also served as Chairman of the Department of Medicine at Inova Fairfax Hospital and was Inova Health Systems Medical Director of Research and Education. During his tenure there, multiple specialties within his department were cited in US News and World Report’s annual list of top hospital programs. Dr. Cooper has over 25 years of experience in clinical research and has presented scientific papers and authored multiple publications. He received his BA from Columbia University and an MD from New York University, as well as obtaining additional training at Georgetown University Hospital, Boston City Hospital and the University of Chicago. He also completed the Management Development Program for Physician Executives at The University of Pennsylvania’s Wharton School of Business.

Luis T. Gutierrez., JR. – President and chief executive officer

Mr. Gutierrez joined the company in 2014 as President and Chief Executive Officer.   He also serves on the company’s Board of Directors. Mr. Gutierrez has over 25 years of experience in helping companies that develop novel medical technologies with scientific and clinical promise make the transition to becoming successful commercial enterprises.  He has held management roles with Merck, Covance, MedAssurant, and, most recently, Aptiv Solutions, where he served as Executive Vice President and Chief Commercial Officer.  He helped position that company for its successful sale to a strategic buyer in early 2014.   Prior to that, he was with Covance (NYSE: CVD) for over 19 years, ultimately serving as President of the Commercialization Services division and as a member of Covance’s Global Leadership Council.   Mr. Gutierrez received a Bachelor of Arts, with honors, from Harvard University and a Master of Business Administration degree from Stanford University’s Graduate School of Business.

Mitchell p. cybulski

Mr. Mitchell P. Cybulski, Mitch, M.B.A. served as President for Japan/Pacific of SmithKline Beecham PLC from 1991 to 1993.  Mr. Cybulski was responsible for pharmaceutical and vaccine businesses in Southeast Asia, China, Japan, Australian and New Zealand.  From 1985 to 1991, he served as President for Japan of Bristol-Myers Squibb.  From 1982 to 1985, Mr. Cybulski served as President of Mead Johnson, Canada, a subsidiary of Bristol-Myers.  Before that, he served in various capacities in Finance and General management of Bristol-Myers.  Mr. Cybulski served as Chairman of SmithKline Beecham International from 1993 to 2000, where he was responsible for all pharmaceutical, vaccine and consumer sales for all territories outside of North America and Europe.  He has more than thirty years’ experience in senior management positions within the pharmaceutical industry.  He has been Director of Biopro Pharmaceutical, Inc. since January 2006.  He serves as a Director of EMX International, LLC.  He serves on the board of stem cell company OmniCyte Ltd. And medical device company EMcision, Ltd.  He served as a Director at ScriptRx, Inc.  He served as Director of Spectrum Pharmaceuticals, Inc. from July 2007 to July 2010.  Mr. Cybulski holds a BBA from the University of Texas at Arlington and holds an M.B.A. from Columbia University.

William D. King

Mr. King has held several executive positions including CEO of Aviation Distributors Inc., a consultant to McCrory Corp. providing successful turnaround guidance for McCrory Stores, Executive Vice President and President of the Electrical and Mechanical Groups of JWP, Inc. and President and Chief Operating Officer of International Technology Corporation. Mr. King began his career as a Senior Consultant with McKinsey and Company, Inc. in 1969 after graduating from Harvard Business School. He graduated from the University of North Carolina in 1964 and served as a Captain in the U. S Marine Corps.

Kevin G. Quinn

President of Wye River Group, Mr. Quinn has over 30 years of corporate and project finance experience. From 1979 to 1982, Mr. Quinn was an attorney at Miles & Stockbridge in Baltimore. From 1982 to 1994, Mr. Quinn was employed as an investment banker at Alex. Brown & Sons, where he progressed from the positions of Associate to Managing Director, and served during his last four years there as head of the firm’s Public Finance Department. In 1994, Mr. Quinn became Managing Director and head of Investment Banking for H.C. Wainwright & Co. in Boston. During his tenure at Alex. Brown and Wainwright, Mr. Quinn also served as lead banker or advisor on over 200 engagements comprising public and private offerings of equity and debt securities, mergers and acquisitions and divestitures. In 1999, Mr. Quinn launched Wye River Group which focuses on providing financial advisory, capital financing and investment advisory services to institutional clients. Mr. Quinn is a graduate of the University of Maryland Business School (MBA), University of Maryland Law School and Loyola College (BA). In addition to his activities at Wye River Group, Mr. Quinn serves on the boards of directors of CareFirst, Inc. (Blue Cross/Blue Shield) and Securities Finance Trust Company. He has previously served on the boards of Merge Healthcare (NASDAQ: MRGE) and Old Mutual Asset Management Trust Company.

Barry S. Strauch, M. D.

Dr. Barry S. Strauch has been an active member of the medical staff at Inova Fairfax Hospital for 37 years, serving for 24 years as Chief of the Nephrology Section and for the past five and a half years as Interim Chairman of the Department of Medicine. Dr. Strauch co-founded and served as Chairman of Washington Nephrology Associates, a regional practice and one of the two largest nephrology practices in the United States. He served as Chairman of a quasi-government agency (one of 32 networks in the United States) which regulated quality and need for dialysis and transplantation and as a member of the executive committee of the national forum of such networks. Dr. Strauch has been an active clinical teacher in both general Internal Medicine and Nephrology, and has published a significant number of papers investigating research topics in dialysis grafts and transplant rejection. He won the Vernon K. Vance, M.D. Memorial Award for long-standing teaching excellence. He currently serves as Clinical Professor of Medicine at the Medical Schools of Georgetown, George Washington, and Virginia Commonwealth University and as a trustee on the Board of Johns Hopkins Medicine. He has previously served on the Board of Vapotherm. He is the recipient of the 2009 Laureate Award by the Virginia branch of the American College of Physicians for long-term contributions to the field of Internal Medicine. Dr. Strauch attended the Johns Hopkins University Medical School and later completed his training in Internal Medicine and Metabolism at Yale and N.I.H.

Dendy Young, M.B.A.

Mr. Young is currently the Managing Partner of McLean Capital, LLC, a private equity firm, based in McLean, VA, which focuses on investments in government information technology as well as other angel investments.  He is a member of Blu Venture Investors, a venture capital investment company that supports early stage companies in the Washington DC area.  From January 1996 to 2006, Mr. Young was CEO of GTSI Corp. (NASDAQ: GTSI), an enterprise services and solutions provider. Prior to GTSI, Mr. Young served as Chief Executive Officer of Falcon Microsystems, Inc., the second of two privately held, Federally-focus IT companies he founded, and Falcon Systems, Inc.  Mr. Young serves on the Executive Committee of the Northern Virginia Technology Council (NVTC), where he holds the position of Chairman of the NVTC TechPAC (Political Action Committee), and on the Boards of the AFCEA Educational Foundation and the Washington Airports Task Force.  He is Chairman of the Board of Navanti Group, LLC, which specializes in risk assessment and the use of social media in countering violent extremism, Qlarion, Inc., which provides expertise in business intelligence, Icaros, which delivers GIS solutions to government and industry, and Personalized Cancer Therapy (Perthera), a company that provides oncologists with personalized recommendations for their patients.  In addition, Mr. Young is on the boards of Omnilink Systems, Inc. a location-based-services company, Core2, which mines big data from the Internet, and Internet Broadcasting Corporation (Vibble), which streams foreign television channels to the US.  Mr. Young holds a S.B. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology and an M.B.A. from the Harvard Business School.